Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

JPM Session Predicts Mixed Outlook

Executive Summary

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.

You may also be interested in...



Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?

Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.

China Alzheimer's Approval Raises Hope But Also Questions

While the approval in China of a novel algae-derived drug for Alzheimer's appears to be a breakthrough, it has also left some wondering about long-term efficacy and the reasons for the apparent rush to grant the clearance ahead of a major pending filing for the disease in the US.

Stress Test: Coronavirus Challenges China Emergency Approval Mechanism

A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141535

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel